EVMN Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 7.47%, SMA50 28.22%, SMA200 30.82%). The stock’s 14-day RSI is 54.91 (neutral), while the ATR of 3.21 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -19.79% below its high and over 91.79% above its low. Average 10-day trading volume of 320.64 thousand shares is below the 3-month average of 643.55 thousand, indicating normal recent market interest.

Analyst sentiment is bullish. Analyst rating data shows there are 6 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $65.00 to $35.00. The high target offers 144.09% upside. The low target suggests 31.43% downside. The mean target is $45.10. This offers 69.36% upside. Evommune, Inc. earnings surprise history is a mixed track record. The quarter that ended December 11, 2025, missed forecasts by 623.77%. The prior quarter beat by -5.02%. Over the last six quarters, Apple has recorded several small beats. These include -5.02% in December 03, 2025.

Evommune, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$24.64. This means the shares are trading below this model’s fair value.

Evommune, Inc. (NYSE:EVMN) closed at $27.32 USD, gaining $0.38 (1.43%) from the previous close of $26.94. The stock is currently mid-range between its 52-week high and low $13.88 and $33.20. With a market capitalization of about $351.71 million, Evommune, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~2.31). Key stats such as the average daily volume over the past year has been around 629.40 thousand shares, volume is running light vs its 52-week average. Headquartered in Palo Alto, CA, Evommune, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Luis C. Pena, the company employs approximately 45 people and listed since November 06, 2025. Evommune, Inc. operates as a clinical-stage biotechnology company in the United States.

Evommune, Inc. (NYSE:EVMN) shares are flat 7.48% year-to-date currently trading near 52-week highs band. Valuation shows Evommune, Inc. trading at a premium to the broader market with a P/E of -11.94. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $45.10, suggesting 69.36% upside. Our AI forecast model points to short-term strength (8.41% over two weeks), a medium-term fall (-3.83% over three months), and a longer-term gain (57.49% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Evommune, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 8.41%, with price expected at $28.87 by April 28, 2026, within a range of $27.28 to $30.50 3-Month Outlook: Projected fall of -3.83%, reaching $25.61 by July 13, 2026, with a range of $25.01 to $26.09. 1-Year Outlook: Projected gain of 57.49%, with price at $41.94 by April 14, 2027, within a range of $41.47 to $42.52.

Evommune, Inc. trades at a P/E ratio of -11.94, slightly below the S&P 500 average, with a price-to-sales ratio of 25.83 and a price-to-book ratio of 4.0 trading at moderately above to book value. The P/FCF stands at -4.38, also below market averages.